FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens
20 December 2019 -- AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2019 Category: Drugs & Pharmacology Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Investor Update - December 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Grants Breakthrough Therapy Designation for Tucatinib in HER2-Positive Breast Cancer
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Patrick I. Borgen, MD, Discusses Treatment Advances to Watch for in HER2-Positive Breast Cancer
The breast cancer expert discussed 2 advances in HER2-positive breast cancer treatment that healthcare providers should look for. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Patrick I. Borgen, MD Source Type: news

Scientists make 'exciting' advancement in certain breast cancer drugs
Two new drug treatments for HER2-positive breast cancer were tested in separate studies. One study involves the drug Tucatinib, and the other involves an antibody-drug called trastuzumab deruxtecan. (Source: CNN.com - Health)
Source: CNN.com - Health - December 18, 2019 Category: Consumer Health News Source Type: news

Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer
Trastuzumab emtansine showed no disease-free survival or safety advantage over paclitaxel + trastuzumab in the adjuvant setting for patients with stage 1 HER2-positive breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Foundation Medicine Expands Companion Diagnostics Offerings
FoundationOne CDx has earned yet another approval from FDA, making the companion diagnostic now available for 19 FDA-approved targeted therapies. It can now be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. FDA approved Piqray in May 2019, and it is the first and only treatment specifically for patients with a PIK3CA mutation i...
Source: MDDI - December 12, 2019 Category: Medical Devices Authors: Daphne Allen Tags: IVD Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 12, 2019 Category: Pharmaceuticals Source Type: news

SABCS: Addition of Tucatinib Ups Survival in HER2 + Metastatic Breast Cancer
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2019 Category: Cancer & Oncology Tags: Gynecology, Neurology, Oncology, Pharmacy, Conference News, Source Type: news

Updated APHINITY Supports Benefit of Dual HER2 Blockade Updated APHINITY Supports Benefit of Dual HER2 Blockade
A new analysis some 6 years after randomization continues to support dual HER2 blockade plus chemotherapy for HER2-positive early breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Targeted therapy drug helps women with aggressive breast cancer live longer
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy significantly improves overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common types of the disease.The findings also show the combination treatment is beneficial at the time of recurrence and should become a first-line option in postmenopausal women with HR+/HER2- advanced breast cancer.The study was published today in the New England Journal of Medicine and presented earlier this year at the European Society for Medical Oncology Congress in...
Source: UCLA Newsroom: Health Sciences - December 11, 2019 Category: Universities & Medical Training Source Type: news

Two New Breast Cancer Drugs Show Promise In Early Trials
Women with HER2-positive breast cancer may soon have some brand new treatment options after two experimental drugs performed well in clinical trials. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 11, 2019 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Source Type: news

New Standard Likely for Some Metastatic HER2 Breast Cancer New Standard Likely for Some Metastatic HER2 Breast Cancer
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SABCS: Addition of Tucatinib Ups Survival in HER2 & #43; Metastatic Breast Cancer
WEDNESDAY, Dec. 11, 2019 -- Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2019 Category: Pharmaceuticals Source Type: news

Dana-Farber Study: New Drugs Show Rare Promise Against Advanced Breast Cancer
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target. “It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 11, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news

' Compelling' Data on New Agent in Pretreated Breast Cancer'Compelling' Data on New Agent in Pretreated Breast Cancer
Trastuzumab deruxtecan generated durable responses in HER2-positive metastatic breast cancer that had progressed on trastuzumab emtansine and other therapies in a phase 2 study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

APHINITY six-year results strengthen evidence of clinical benefit with Roche ’s Perjeta-based regimen
Roche the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2019 Category: Pharmaceuticals Source Type: news

APHINITY six-year results strengthen evidence of clinical benefit with Roche ’s Perjeta-based regimen
             Basel, 11 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC). This latest int...
Source: Roche Investor Update - December 11, 2019 Category: Pharmaceuticals Source Type: news

Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens. (Source: World Pharma News)
Source: World Pharma News - December 11, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

HER2-Positive Breast Cancer
Title: HER2-Positive Breast CancerCategory: Diseases and ConditionsCreated: 12/11/2019 12:00:00 AMLast Editorial Review: 12/11/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 11, 2019 Category: Cancer & Oncology Source Type: news

Tucatinib 'game changing' against HER2+ breast cancer, especially with brain metastases
(University of Colorado Anschutz Medical Campus) Phase III results at NEJM and SABCS: Adding tucatinib to standard of care treatment nearly tripled one-year progression-free survival. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2019 Category: International Medicine & Public Health Source Type: news

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2019 Category: Cancer & Oncology Source Type: news

Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Addition of Pertuzumab to Previous Standards Improves IDFS in HER2+ Breast Cancer
The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Trastuzumab Deruxtecan Shows Promise in Heavily Pretreated Patients With HER2+ BC
T-DXd demonstrated improved and durable response rates in heavily pretreated patients with advanced HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Frequency and Outcomes of Brain Metastases in Patients With HER2-Mutant Lung Cancers
Patients with metastatic non-small cell lung cancer who harbor HER2-mutations may develop brain metastases more frequently during treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 10, 2019 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Black Diamond Therapeutics Closes $85 Million Series C Financing
Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors CAMBRIDGE, Mass. and NEW YORK, Dec. 5, 2019 -- (Healthcare Sales & Marketing Network) -- Black Diamond Therapeutics, Inc., a precision oncology medicin... Biopharmaceuticals, Oncology, Venture Capital, Personnel Black Diamond Therapeutics, EGFR, HER2, precision medicine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Predicting Chemo Benefit in Breast Cancer With EndoPredict Predicting Chemo Benefit in Breast Cancer With EndoPredict
Can a clinicomolecular score reliably predict absolute benefit of chemotherapy in women with HER2-negative, ER-positive breast cancer?JCO Precision Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

OHSU spinout raised $1.5M for cancer drug platform
An Oregon Health& Science University spinout raised $1.5 million, which will help advance its cancer drug candidate toward a clinical trial. PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni& Joan E. Kuni Foundation, based in Vancouver. The funding is part of a $4 million offering, according to a filing with the U.S. Securities& Exchange Commission. PDX Pharmaceuticals’ first drug candidate is targeted for treatment of HER2-positive breast cancer, which accounts for… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 3, 2019 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

OHSU spinout raised $1.5M for cancer drug platform
An Oregon Health& Science University spinout raised $1.5 million, which will help advance its cancer drug candidate toward a clinical trial. PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni& Joan E. Kuni Foundation, based in Vancouver. The funding is part of a $4 million offering, according to a filing with the U.S. Securities& Exchange Commission. PDX Pharmaceuticals’ first drug candidate is targeted for treatment of HER2-positive breast cancer, which accounts for… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 3, 2019 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

Phase III HLX02 Study Meets Primary End Point in Patients with HER2+ Breast Cancer
Henlius announced that their multicenter phase III study met its primary end point of best overall response rate at week 24. (Source: CancerNetwork)
Source: CancerNetwork - November 26, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
(European Society for Medical Oncology) The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2019 Category: Pharmaceuticals Source Type: news

CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer CDK4/6 Combo Better Than Chemo in Advanced Breast Cancer
A new study confirms that a CDK4/6 blocker plus endocrine therapy is better than chemotherapy in young women with HR+, HER2- metastatic disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Treatment with anti-cancer drug T-DM1 after pertuzumab is 'good option'
(European School of Oncology) Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T-DM1 -- a drug that combines trastuzumab with an anti-cancer drug called DM1. The research is presented at the Advanced Breast Cancer Fifth International Consensus Conference (ABC5) and published simultaneously in published in Clinical Breast Cancer journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2019 Category: Cancer & Oncology Source Type: news

Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma Palbociclib With Endocrine Therapy for HR+ Breast Carcinoma
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

First HER2/4-1BB Bispecific Molecule Shows Clinical Activity in HER2+ Cancers
PRS-343, a HER2/4-1BB targeting bispecific construct, is well-tolerated and demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types. (Source: CancerNetwork)
Source: CancerNetwork - November 11, 2019 Category: Cancer & Oncology Authors: Brittany Lovely Source Type: news

Trial Results Support Frontline Use of T-DM1 in HER2 ‐Positive Metastatic Breast Cancer
Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2 ‐positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 9, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

HER2/HER3 Antibody Therapeutic Shows Potential in NRG1-Fusion-Positive Solid Tumors
MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions. (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

What Is the Risk of Recurrence in HER2-Positive Breast Cancer?
Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis. (Source: CancerNetwork)
Source: CancerNetwork - October 24, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Tucatinib Improves PFS, OS in HER2-Positive Metastatic Breast Cancer
Tucatinib showed improvements in survival in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 24, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Metastatic Breast Cancer Highlights From ESMO 2019 Metastatic Breast Cancer Highlights From ESMO 2019
Metastatic breast cancer highlights from ESMO 2019 confirm that CDK4/6 inhibition gives survival benefit in HR+/HER2- breast cancer and that immunotherapy is active in the neoadjuvant setting in TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news

Addition of Abemaciclib to Fulvestrant Improves OS in HR+, HER2- Advanced Breast Cancer
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients. (Source: CancerNetwork)
Source: CancerNetwork - October 18, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. (Source: World Pharma News)
Source: World Pharma News - October 17, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

What Factors Can Predict Response to HER2-Directed Neoadjuvant Therapy?
Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study. (Source: CancerNetwork)
Source: CancerNetwork - October 16, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news